posted on 2020-12-09, 16:39authored byVera F.
C. Ferreira, Bruno L. Oliveira, Alice D’Onofrio, Carlos M. Farinha, Lurdes Gano, António Paulo, Gonçalo J. L. Bernardes, Filipa Mendes
Pretargeted
imaging has emerged as an effective multistep strategy
aiming to improve imaging contrast and reduce patient radiation exposure
through decoupling of the radioactivity from the targeting vector.
The inverse electron-demand Diels–Alder (IEDDA) reaction between
a trans-cyclooctene (TCO)-conjugated antibody and
a labeled tetrazine holds great promise for pretargeted imaging applications
due to its bioorthogonality, rapid kinetics under mild conditions,
and formation of stable products. Herein, we describe the use of functionalized
carbonylacrylic reagents for site-specific incorporation of TCO onto
a human epidermal growth factor receptor 2 (HER2) antibody (THIOMAB)
containing an engineered unpaired cysteine residue, generating homogeneous
conjugates. Precise labeling of THIOMAB–TCO with a fluorescent
or radiolabeled tetrazine revealed the potential of the TCO-functionalized
antibody for imaging the HER2 after pretargeting in a cellular context
in a HER2 positive breast cancer cell line. Control studies with MDA–MD-231
cells, which do not express HER2, further confirmed the target specificity
of the modified antibody. THIOMAB–TCO was also evaluated in
vivo after pretargeting and subsequent administration of an 111In-labeled tetrazine. Biodistribution studies in breast cancer tumor-bearing
mice showed a significant activity accumulation on HER2+ tumors, which was 2.6-fold higher than in HER2– tumors. Additionally, biodistribution studies with THIOMAB without
the TCO handle also resulted in a decreased uptake of 111In–DOTA–Tz on HER2+ tumors. Altogether,
these results clearly indicate the occurrence of the click reaction
at the tumor site, i.e., pretargeting of SK-BR-3 HER2-expressing cells
with THIOMAB–TCO and reaction through the TCO moiety present
in the antibody. The combined advantages of site-selectivity and stability
of TCO tagged-antibodies could allow application of biorthogonal chemistry
strategies for pretargeting imaging with minimal side-reactions and
background.